---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-23-000042"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:42:05.237652+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Salarius raises $6M in private placement of common stock and warrants

## Summary
- Issued 3,636,364 shares (or pre-funded warrants) plus Series A-1 and A-2 warrants at $1.65/unit.
- Gross proceeds ~$6.0M; H.C. Wainwright acted as exclusive placement agent (7% fee).
- Series A-1 warrants exercisable at $1.40 for 5.5 years; Series A-2 at $1.40 for 18 months.
- Proceeds to fund product development and working capital; closing occurred May 16, 2023.
- Registration statement for resale of securities to be filed within 15 days.

## SEC filing metadata
- accession: 0001615219-23-000042
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000042/0001615219-23-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000042/flks-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-23-000042
- JSON: https://secwatch.observer/filing/0001615219-23-000042.json
- Plain text: https://secwatch.observer/filing/0001615219-23-000042.txt

## Key facts
- Material Agreements
  Decoy Therapeutics Inc. entered into Registration Rights Agreement with an accredited investor (effective 2023-05-11).
  - Action: entry
  - Counterparty: an accredited investor
  - Effective: 2023-05-11
  source text: In connection with the Offering, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor pursuant to which the Company shall prepare and file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement covering the Shares sold in the Offering and the shares of Common Stock issuable upon exercise of the Warrants on or prior to the date that is 15 calendar days following the date of the Registration Rights Agreement (the “Filing Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000042/0001615219-23-000042-index.htm
- Material Agreements
  Decoy Therapeutics Inc. entered into Securities Purchase Agreement with an accredited investor valued at approximately $6.0 million (effective 2023-05-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an accredited investor
  - Value: approximately $6.0 million
  - Effective: 2023-05-11
  source text: On May 11, 2023, Salarius Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a private placement (the “Offering”) (i) 330,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,306,364 shares of Common Stock, (iii) Series A-1 warrants (the “Series A-1 Warrants”) to purchase up to 3,636,364 shares of Common Stock and (iv) Series A-2 warrants (the “Series A-2 Warrants” and together with the Series A-1 Warrants, the “Common Stock Warrants,” and together with the Pre-Funded Warrants, the “Warrants”) to purchase up to 3,636,364 shares of Common Stock, at a purchase price of (a) $1.65 per Share and accompanying Common Stock Warrants and (b) $1.6499 per Pre-Funded Warrant and accompanying Commo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000042/0001615219-23-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.